Mesoblast Ltd. (MSB) and Lonza reported that they have entered into an agreement for commercial manufacture of Mesoblast’s lead allogeneic (off-the-shelf) cell therapy product candidate, remestemcel-L for pediatric steroid-refractory acute graft versus host disease (aGVHD)
http://crweworld.com/article/news-provided-by-globenewswire/1276938/mesoblast-and-lonza-enter-into-agreement-for-commercial-manufacture-of-mesoblasts-potential-first-united-states-allogeneic-cell-therapy
Mesoblast Ltd. (MSB) and Lonza reported that they have entered...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
-0.038(3.19%) |
Mkt cap ! $1.341B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.19 | $1.13 | $2.864M | 2.479M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 13214 | 6 |
View Market Depth
| Last trade - 10.16am 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.13 |
Change
-0.038 ( 4.33 %) |
||||
| Open | High | Low | Volume | ||
| $1.17 | $1.17 | $1.12 | 430882 | ||
| Last updated 10.34am 08/05/2024 ? | |||||
| MSB (ASX) Chart |